Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
We propose to build on preliminary data evaluating non-dopaminergic/non-motor clinical
biomarkers to more fully assess these markers at the threshold of Parkinson disease (PD).
Development of reliable biomarkers for both dopaminergic and non-dopaminergic manifestations
of Parkinson disease (PD) and related disorders may dramatically accelerate research on PD
etiology, pathophysiology, and therapeutics. Biomarkers are broadly defined as
characteristics that are objectively measured and evaluated as indicators of normal
biological processes, pathogenic processes, or pharmacologic responses to a therapeutic
intervention. Specific biomarkers may be useful at the onset of neurodegeneration, the onset
of disease, and/or to mark disease progression.
Phase:
Phase 2
Details
Lead Sponsor:
Institute for Neurodegenerative Disorders
Collaborators:
Molecular NeuroImaging United States Department of Defense